As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China
This article was originally published in The Pink Sheet Daily
The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.
You may also be interested in...
BEIJING - The financial meltdown and widening layoffs in the United States, combined with Beijing's injection of stimulus funds into its pharmaceutical and biotech sectors, could trigger a reverse brain drain in those sectors, according to industry insiders and investors in the U.S. and China
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.